nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

28.08.2019 | Original Article

Clinical outcomes of patients with pure small cell carcinoma of the urinary bladder

verfasst von: Gokmen Umut Erdem, Mutlu Dogan, Aydin Aytekin, Suleyman Sahin, Havva Yeşil Cinkir, Abdullah Sakin, Melike Ozcelik, Oktay Bozkurt, Emel Sezer, Nebi Serkan Demirci, Yakup Bozkaya, Nurullah Zengin

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

There is not yet a standardized approach to treat patients with small cell carcinoma of the bladder (SmCCB). This study aims to investigate the clinical features, treatment, and survival outcomes of patients with pure SmCCB.

Materials and methods

Patients diagnosed with SmCCB between January 2006 and September 2015 were retrospectively evaluated.

Results

A total of 34 patients with a median age of 63.0 years were included in the study, with a male to female ratio of 4.6:1.0. At the time of diagnosis, 22 patients (64.7%) had stage IV disease. At a median follow-up time of 12.7 months, 67.6% of patients died of bladder carcinoma, with an overall survival (OS) of 15.7 months for all patients. In the patients with stages I–III, nodal involvement, and distant metastases, the median OS was 31.8, 15.7, and 8.4 months, respectively (P = 0.005). Considering the survival rates of the patients (stages I–III) treated with surgery vs. local therapy, there was not a statistically significant difference (26.6 months and 31.8 months, P = 0.97, respectively). A multivariate analysis revealed that stage IV disease and poor ECOG performance status were associated with OS.

Conclusion

The optimal treatment of SmCCB has been under debate. For the patients with advanced stage of disease (T4b, N+, M+), platinum containing chemotherapeutic agents should be preferred. Stage IV disease and poor ECOG performance status were associated with shorter OS.

Erdem GU, Ozdemir NY, Demirci NS et al (2016) Small cell carcinoma of the urinary bladder: changing trends in the current literature. Curr Med Res Opin 32(6):1013–1021. https://doi.org/10.1185/03007995.2016.1155982 CrossRefPubMed

Cramer SF, Aikawa M, Cebelin M (1981) Neurosecretory granules in small cell invasive carcinoma of the urinary bladder. Cancer. 47(4):724–730CrossRef

Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG (2005) Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology. 46(1):57–63. https://doi.org/10.1111/j.1365-2559.2004.01980.x CrossRefPubMed

Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, Kuzel TM, Papavero V, Tretiakova M, Nigro K, Koch MO, Eble JN (2004) Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer. 101(5):957–962. https://doi.org/10.1002/cncr.20456 CrossRefPubMed

Choong NW, Quevedo JF, Kaur JS (2005) Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 103(6):1172–1178. https://doi.org/10.1002/cncr.20903 CrossRefPubMed

Vakar-Lopez F, True LD (2007) How wide is the spectrum of neuroendocrine carcinoma of the urinary bladder? Am J Clin Pathol 128(5):723–725. https://doi.org/10.1309/N5N5Y8VD90W91WQP CrossRefPubMed

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL (2010) AJCC Cancer staging manual, 7th edn, pp 497–502

Ismaili N, Heudel PE, Elkarak F, Kaikani W, Bajard A, Ismaili M, Errihani H, Droz JP, Flechon A (2009) Outcome of recurrent and metastatic small cell carcinoma of the bladder. BMC Urol 9(4). https://doi.org/10.1186/1471-2490-9-4.

Pasquier D, Barney B, Sundar S, Poortmans P, Villa S, Nasrallah H, Boujelbene N, Ghadjar P, Lassen-Ramshad Y, Senkus E, Oar A, Roelandts M, Amichetti M, Vees H, Zilli T, Ozsahin M (2015) Small cell carcinoma of the urinary bladder: a retrospective, multicenter rare cancer network study of 107 patients. Int J Radiat Oncol Biol Phys 92(4):904–910. https://doi.org/10.1016/j.ijrobp.2015.03.019 CrossRefPubMed

10.

Chen Z, Liu Q, Chen R, Liu Z, Li M, Ling Q, Wu L, Yang J, Liu X, Wang T, Hu Z, Guo X, Wang S, Yang W, Liu J (2017) Clinical analysis of small cell carcinoma of the bladder in Chinese: nine case reports and literature reviews. World J Surg Oncol 15(1):33. https://doi.org/10.1186/s12957-016-1079-y. CrossRefPubMedPubMedCentral

11.

Koay EJ, Teh BS, Paulino AC, Butler EB (2011) A surveillance, epidemiology, and end results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends. Cancer. 117(23):5325–5333. https://doi.org/10.1002/cncr.26197 CrossRefPubMed

12.

Hou CP, Lin YH, Chen CL et al (2013) Clinical outcome of primary small cell carcinoma of the urinary bladder. Onco Targets Ther 6:1179–1185. https://doi.org/10.2147/OTT.S49879 CrossRefPubMedPubMedCentral

13.

Ploeg M, Aben KK, Hulsbergen-van de Kaa CA et al (2010) Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. J Urol 183(3):915–920. https://doi.org/10.1016/j.juro.2009.11.018 CrossRefPubMed

14.

Bhatt VR, Loberiza FR Jr, Tandra P, Krishnamurthy J, Shrestha R, Wang J (2014) Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder. Rare Tumors 6(1):5043–5014. https://doi.org/10.4081/rt.2014.5043 CrossRefPubMedPubMedCentral

15.

Balar A, Bajorin DF, Milowsky MI (2011) Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy. Ther Adv Urol 3(3):107–117. https://doi.org/10.1177/1756287211407543 CrossRefPubMedPubMedCentral

16.

Schreiber D, Rineer J, Weiss J, Leaf A, Karanikolas N, Rotman M, Schwartz D (2013) Characterization and outcomes of small cell carcinoma of the bladder using the surveillance, epidemiology, and end results database. Am J Clin Oncol 36(2):126–131. https://doi.org/10.1097/COC.0b013e3182438c71 CrossRefPubMed

17.

Patel SG, Stimson CJ, Zaid HB, Resnick MJ, Cookson MS, Barocas DA, Chang SS (2014) Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. J Urol 191(2):329–334. https://doi.org/10.1016/j.juro.2013.09.009 CrossRefPubMed

18.

Koay EJ, Teh BS, Paulino AC, Butler EB (2012) Treatment trends and outcomes of small-cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 83(1):64–70. https://doi.org/10.1016/j.ijrobp.2011.05.039 CrossRefPubMed

19.

Mattes MD, Kan CC, Dalbagni G, Zelefsky MJ, Kollmeier MA (2015) External beam radiation therapy for small cell carcinoma of the urinary bladder. Pract Radiat Oncol 5(1):e17–e22. https://doi.org/10.1016/j.prro.2014.03.013 CrossRefPubMed

20.

Kaushik D, Frank I, Boorjian SA, Cheville JC, Eisenberg MS, Thapa P, Tarrell RF, Thompson RH (2015) Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. Int J Urol 22(6):549–554. https://doi.org/10.1111/iju.12729 CrossRefPubMed

21.

Quek ML, Nichols PW, Yamzon J et al (2005) Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern California experience. J Urol 174(1):93–96. https://doi.org/10.1097/01.ju.0000162085.20043.1f CrossRefPubMed

22.

Siefker-Radtke AO, Dinney CP, Abrahams NA et al (2004) Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol 172(2):481–484CrossRef

23.

Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE (2009) Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 27(16):2592–2597. https://doi.org/10.1200/JCO.2008.19.0256 CrossRefPubMedPubMedCentral

24.

Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A (2013) Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol 64(2):307–313. https://doi.org/10.1016/j.eururo.2012.04.020 CrossRefPubMed

25.

Eswara JR, Heney NM, Wu CL, McDougal WS (2015) Long-term outcomes of organ preservation in patients with small cell carcinoma of the bladder. Urol Int 94(4):401–405. https://doi.org/10.1159/000366522 CrossRefPubMed

Titel: Clinical outcomes of patients with pure small cell carcinoma of the urinary bladder
verfasst von: Gokmen Umut Erdem
Mutlu Dogan
Aydin Aytekin
Suleyman Sahin
Havva Yeşil Cinkir
Abdullah Sakin
Melike Ozcelik
Oktay Bozkurt
Emel Sezer
Nebi Serkan Demirci
Yakup Bozkaya
Nurullah Zengin
Publikationsdatum: 28.08.2019
Verlag: Springer London
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 2/2020
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-019-02074-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objectives

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Interventions to improve wellbeing among obstetricians and midwives at Cork University Maternity Hospital

Evaluation and management of pathological nipple discharges without using intraductal imaging methods

Professional burnout, work patterns and career satisfaction in medical oncologists in Ireland

“A breath of fresh air” for tackling chronic disease in Ireland? An evaluation of a self-management support service for people with chronic respiratory diseases

Malignant but not maleficent: acute leukaemia as a possible explanation of disease and death in vampire victims

Accidental dural puncture and post-dural puncture headache: a retrospective review in an Irish maternity hospital